Thoracic Fluid Content by Bioimpedance-based Starling System
NCT ID: NCT05676723
Last Updated: 2023-01-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
41 participants
OBSERVATIONAL
2022-01-18
2022-11-02
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Thoracic Fluid Assessment by Contrast-enhanced Magnetic Resonance Imaging and Bioimpedance
NCT02364193
Thoracic Fluid Content as an Outcome Predictor in Intensive Care Unit
NCT07100821
Thorathic Fluid Content as an Early Predictor of Weaning From Mechanical Ventilation in Acute Respiratory Distress Syndrome
NCT06233448
A Portable Thoracic Impedance Device for Detecting Pulmonary Congestion in Heart Failure Patients
NCT06604468
Measurement of Cardiac Output in Intensive Care Unit With Unstable Hemodynamic: Validation of Physioflow® Device Versus Trans Thoracic Echocardiography
NCT03937102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalization in an ICU
* Monitoring by transpulmonary thermodilution already in place
* Decision by clinicians in charge to perform volume expansion by saline or fluid removal by diuretics infusion and/or ultrafiltration ("Fluid" group)
* Or presence of Acute Respiratory Distress Syndrome according to the Berlin definition ("ARDS" group)
Exclusion Criteria
* In "Fluid" group, circulatory failure whose treatment cannot be postponed for ≥5 minutes (time required for the installation of Starling system).
* Impossibility to paste bioreactance electrodes properly in the skin of the thorax.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bicetre Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xavier Monnet
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Kremlin-Bicetre
Le Kremlin-Bicêtre, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A02825-50
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.